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In Brief
Impairment of the NRF2 pathway is a key contributor to premature aging in Hutchinson-Gilford progeria syndrome (HGPS) via increasing chronic oxidative stress that recapitulates HGPS aging defects.
INTRODUCTION
Aging is a fundamental biological process linked to many common diseases, including cancer and cardiovascular disease. The naturally occurring human premature aging disorder Hutchinson-Gilford progeria syndrome (HGPS) is a powerful tool to study human aging (Gordon et al., 2014) . In HGPS a de novo mutation in the LMNA gene, encoding for the nuclear architectural proteins lamin A and C, activates an alternative pre-mRNA splice site, resulting in the expression of a lamin A mutant lacking 50 amino acids (aa), known as progerin, which undergoes incomplete posttranslational processing and consequently retains a farnesylated C-terminal CaaX motif (Gordon et al., 2014) . Progerin is also thought to be relevant to the normal aging process, since sporadic usage of the same alternative splice site results in accumulation of progerin during physiological aging (Rodriguez et al., 2009; Scaffidi and Misteli, 2006) . Progerin acts in a dominant fashion and causes a variety of cellular defects that compromise the integrity of nuclear architecture, heterochromatin maintenance, DNA repair, and redox homeostasis, and which has been ascribed to reduced levels of key proteins in these pathways (Mateos et al., 2013; Pegoraro et al., 2009; Scaffidi and Misteli, 2006; Viteri et al., 2010) . At an organismal level, in vivo attrition of mesenchymal stem cells (MSCs), prone to the detrimental defects of progerin (Pacheco et al., 2014; Rosengardten et al., 2011; Scaffidi and Misteli, 2008) , is thought to underlie HGPS tissue defects, in line with observations that HGPS-induced pluripotent stem cells (iPSCs)-derived MSCs have reduced viability in hypoxic niches due to diminished capacity to respond to oxidative stress challenges (Liu et al., 2011a (Liu et al., , 2012 Zhang et al., 2011) .
Many of the cellular pathways affected in HGPS are highly interdependent, making it difficult to identify and distinguish cellular factors directly affected by progerin and driving HGPS etiology from those secondarily perturbed downstream of progerin. For example, changes in lamin B1 levels observed in HGPS increase reactive oxygen species (ROS) (Malhas et al., 2009) , which may compromise the nuclear envelope's integrity (Pekovic et al., 2011) . At the same time, ROS may inflict DNA damage and decrease heterochromatin protein levels (Frost et al., 2014) , which, in turn, may activate DNA damage signaling (Pegoraro et al., 2009 ). The complex interdependencies and the wide range of nuclear abnormalities observed in HGPS and in normal aging (Pegoraro et al., 2009; Zhang et al., 2015) points to the involvement of an upstream effector in the disease. A major goal in understanding HGPS and premature aging is the identification of primary driver mechanisms.
We have developed a cell-based high-throughput, high-content imaging small interfering RNA (siRNA) screening assay to directly assess the involvement of individual factors in bringing about HGPS cellular phenotypes in mammalian cells. Using this system, we identify the antioxidant NRF2 pathway as a driver mechanism in HGPS.
RESULTS

A Targeted High-Throughput RNAi Screen to Identify Mediators of Progerin-Induced Aging
We set out to identify human genes that drive the formation of progerin-induced aging defects. To this end, we generated human wild-type (WT) skin fibroblasts containing GFP-progerin under control of a doxycycline-inducible (Tet-on) promoter (see the Experimental Procedures). GFP-progerin was nearly undetectable under normal growth conditions, but on exposure to doxycycline was rapidly induced to levels comparable to endogenous lamin A (Figures S1A and S1B), resulting in the formation of nuclear defects typically observed in HGPS patient skin fibroblasts (Kubben et al., 2015; Musich and Zou, 2009; Scaffidi and Misteli, 2006) , including nuclear shape distortions, decreased levels of the nuclear architectural proteins lamin B1 and LAP2, reduction of heterochromatin-associated HP1g and tri-methylated lysine 27 on histone 3 (H3K27me3) (Figures S1A-S1C and S1F), and increased formation of DNA damage foci containing 53BP1 and serine-139 phosphorylated H2AX (gH2AX; Figures S1A, S1C, and S1F).
Using this inducible model, we performed a high-throughput RNAi screen and searched for genes that simultaneously prevent the occurrence of multiple HGPS phenotypes, including loss of lamin B1, increase of gH2AX, and accumulation of GFP-progerin ( Figure 1A ). Given the widespread involvement of ubiquitin ligases in pathways affected in HGPS and aging (Lö w, 2011) , as well as the observed selective degradation of a set of nuclear proteins in HGPS (Scaffidi and Misteli, 2006) , we used a library containing 320 pools of four siRNAs targeting human ubiquitin E1, E2, and E3 ligases or their direct modulators (Table S3) . The screen was conducted in quadruplicate in a 384-well format by reverse siRNA transfection of GFP-progerin fibroblasts, while simultaneously inducing GFP-progerin expression for 96 hr (see the Experimental Procedures; Figure 1A ). Lamin B1, gH2AX, and GFP-progerin levels were detected by immunofluorescence (IF) and automated high-throughput imaging of 500-2,000 cells per siRNA pool using custom-built image analysis algorithms (see the Experimental Procedures). As a positive control, siRNA directed against GFP efficiently decreased GFP-progerin levels by 95% and prevented formation of lamin B1 and gH2AX defects, as opposed to a non-targeting siRNA that allowed for full development of the HGPS phenotype and served as negative control ( Figures 1A, S1A , and S1C). Z 0 scores ranged from 0.15 to 0.74, depending on the cellular readout (see the Experimental Procedures). We identified seven (2.2%) genes that affected multiple HGPS parameters (Figures 1B and S1J; Tables S2 and  S3 ). All candidates partially downregulated progerin, three prevented formation of lamin B1 defects, and four prevented that increase in gH2AX foci formation. Four of the seven candidates (CAND1, WSB1, FBXO38, and FLJ25076) significantly downregulated progerin and gH2AX protein levels, with a more moderate effect on lamin B1 defects (see the Experimental Procedures) (Table S2) , and were further validated using siRNAs of a different targeting sequence and chemistry to exclude off-target effects.
Among the validated targets, RNAi against CAND1 (cullin-associated NEDD8-dissociated protein 1) had the strongest effect and lowered progerin levels by 47%, prevented lamin B1 loss by 70%, and gH2AX activation by 89% (all p < 0.05; Figures  1C, 1D , S1F, and S1I ; Tables S2 and S3) , making CAND1 a promising candidate for further investigation.
Loss of CAND1 Function Prevents and Reverses HGPS Aging Defects CAND1 is a member of several cullin-containing E3 ubiquitin ligase complexes. CAND1 does not possess ubiquitin ligase activity itself, but functions to modulate the substrate specificity of the E3 ligase complexes (Chua et al., 2011) . In addition to the screening phenotypes, CAND1 knockdown also prevented HGPS-associated reduction of LAP2, HP1g, and H3K27me3 and induction of 53BP1 foci ( Figures 1D and S1G ), while not affecting nuclear shape ( Figure S1H ). Importantly, this protective effect was not merely due to a reduction of progerin levels since lowering induction of progerin in shCTRL-treated cells to levels similar to those in shCAND1-treated cells did not prevent the formation of most defects, except for a minor DNA damage protective effect ( Figure S1K ). CAND1 silencing (À94%; p < 0.05; Figure S1D ) was also sufficient to reverse already established aging defects in HGPS fibroblasts, as it decreased endogenous progerin levels by 46%, restored lamin B1, HP1g, and LAP2 to WT levels, and partially rescued H3K27me3 defects (75%; all p < 0.05; Figures 1E and S1G ). gH2AX and 53BP1 levels remained unchanged (Figures 1E and S1G) , in line with the reported resistance of DNA damage defects in HGPS cells to reversal (Liu et al., 2006) . These data point to a role for CAND1 in a cellular pathway important in establishing and preventing a wide variety of aging defects triggered by progerin.
NRF2-ARE Transcriptional Activity Is Impaired in HGPS
A candidate pathway for the observed CAND1 effects was suggested by the RNAi screening results. Knockdown of the CAND1 interaction partner cullin 3 E3 ligase, but not of other CAND1-interacting cullin proteins tested in the screen, significantly prevented gH2AX foci formation and moderately lowered GFPprogerin levels (À37%, Z = 1.90; Figure S1J ; Table S3 ). In addition, knockdown of RBX1, which interacts with various cullin proteins and is a member of the CAND1/cullin3 complex, prevented formation of lamin B1 defects (Table S3 ; Z = À2.14), but was slightly toxic. These results were of interest given that one of the major substrates of the CAND1/cullin3/RBX1 complex is the transcription factor NRF2 (nuclear factor [erythroidderived 2]-like 2), which has been implicated in organismal longevity and stress resistance by transcriptionally activating antioxidant genes upon binding to antioxidant-responsive elements (ARE) motifs in their promoters (Lewis et al., 2010; Lo and Hannink, 2006; Ma, 2013) . Indeed, CAND1 knockdown increased NRF2 protein levels ( Figure S1E ), in line with previous reports linking the cytoprotective effect of CAND1 knockdown to reduced CAND1/cullin3/ RBX1-mediated NRF2 protein degradation (Lo and Hannink, 2006) .
Given that increased oxidative stress has been implicated in HGPS and normal aging (Viteri et al., 2010) , we set out to determine the status of the NRF2-ARE axis in HGPS. Protein levels of NRF2 and KEAP1, which promote NRF2 degradation via the CAND1/cullin3/RBX1 pathway (Lewis et al., 2010) , were unaffected by progerin in HGPS fibroblasts or upon induction of GFP-progerin in WT cells (Figures 2A, 2B , and S2D). Small MAFs (musculoaponeurotic fibrosarcoma) proteins and CBP, two NRF2 transcriptional co-factors, were also unaffected (Figures 2A, 2B, and S2D) . Considering that the NRF2 pathway is also regulated at the level of nuclear import, we determined nuclear NRF2 protein levels, which were unchanged in HGPS cells in comparison to WT cells ( Figures 2C and 2D (Bloom and Jaiswal, 2003) that could be corrected by a small hairpin RNA (shRNA) targeting progerin ( Figure S2C ). Furthermore, the NRF2-activating compound sulforaphane equally increased nuclear NRF2 levels in the absence or presence of progerin ( Figures S2A and S2B ), indicating that NRF2 protein stability and nuclear-cytoplasmic shuttling is unaffected by progerin. To fully assess the functional status of the NRF2-ARE pathway, we measured its transcriptional activity using AREdriven luciferase constructs . ARE-Luc activity was reduced by 51% in HGPS fibroblasts as a consequence of progerin since induction of GFP-progerin in WT cells resulted in a 77% inhibition of ARE-Luc activity (p < 0.05; Figure 2E ). Gene expression analysis demonstrated that abrogation of the NRF2-ARE axis was a global event since 213 of 774 NRF2-ARE target genes were significantly repressed in HGPS versus WT cells (À0.31 Log2 fold change of average expression; p < 0.0001; Figure 2F ), while no global change was observed for non-NRF2 or HSF1-regulated control genes. Gene set enrichment analysis confirmed an enrichment of NRF2 target genes in WT versus HGPS cells ( Figure S2E ; Table S4 ). We conclude that progerin interferes with NRF2 function by impairing its transcriptional activity.
Progerin Causes NRF2 Mislocalization To investigate potential mechanisms by which progerin interferes with the transcriptional function of NRF2, we probed its subnuclear distribution. Visualization of the NRF2 protein, using a method established to visualize nuclear insoluble fractions (Voncken et al., 2005) , revealed an increased accumulation of NRF2 Targets (*p<0.0001) See also Figure S2 and Table S4. NRF2 at the nuclear periphery and intranuclear aggregates mirroring the distribution of progerin, both in progerin-inducible and HGPS cells, but not in uninduced and WT controls ( Figures  3A-3C , S3A, and S3B). To test whether NRF2 mislocalization may be caused by a differential interaction of NRF2 with progerin compared to WT lamin A, we tested progerin-NRF2 interactions using an orthogonal One-STrEP (OST) pull-down assay in cellular extracts (Kubben et al., 2010) . The interaction of nuclear OST-tagged NRF2 with progerin was strongly enhanced compared to WT lamin A (248%, p < 0.05; Figure 3D ). Conversely, OST-progerin pulled down significantly more NRF2 than OST-lamin A (142%; p < 0.05; Figure 3E ). For further validation, we directly probed progerin-NRF2 interactions in vitro by testing the ability of recombinant NRF2 to bind to streptactin-purified, immobilized OST-lamin A, and OST-progerin. In line with its co-localization and in vivo interaction, NRF2 preferentially bound to OST-progerin (275%; p < 0.05; Figure 3F ). These data suggest that progerin impairs the transcriptional activation of NRF2-ARE regulated antioxidants through sequestration of NRF2 away from its transcriptional targets.
NRF2 Impairment Causes Oxidative Stress and Recapitulates the Progeroid Phenotype
To determine whether abrogation of NRF2 activity contributes to the progeroid phenotype, we investigated the effect of NRF2 knockdown in WT fibroblasts. NRF2 knockdown (À45%; Figures S4A and S4B) was sufficient to recapitulate all tested HGPS defects in WT cells. As expected, NRF2 RNAi increased progerin levels in WT-inducible cells ( Figure S4A ), but further exacerbated nuclear defects in HGPS cells in which NRF2 pathway activity was already suppressed without affecting progerin protein levels ( Figures 4A, 4B , and S4B-S4D), demonstrating that NRF2 affects the establishment of HGPS disease phenotypes by mechanisms other than modulating progerin levels.
In line with NRF2 impairment driving HGPS etiology, NRF2 knockdown in WT fibroblasts reduced expression of antioxidant genes, similarly to the effect of progerin (n = 10, Figures  S4E, S4F , and S5E), thereby increasing ROS levels (+146%, p < 0.05) comparably to HGPS cells (+79%; p < 0.05; Figures  4C and 4D) . Furthermore, elevated levels of oxidative stress itself, induced by H 2 O 2 pro-oxidant treatment, was sufficient for WT fibroblasts to phenotypically mimic HGPS cells for all tested defects, with the anticipated exception of lamin B1 (Barascu et al., 2012) . In line with the NRF2 RNAi experiments, H 2 O 2 treatment of HGPS cells further worsened LAP2, HP1g, H3K27me3, gH2AX, and 53BP1 defects, as well as increased both lamin A (+55%) and progerin (+46%) levels, while not affecting lamin C levels ( Figures 4E, 4F , and S4G). Importantly, the observed increase in progerin levels did not account for lamin B1, LAP2, H3K27me3, and 53BP1 defects since individual cells expressing high levels of progerin had a nearly similar extent of HGPS-associated defects compared the total population of HGPS fibroblasts ( Figure S4J ). These results demonstrate that chronic oxidative stress due to impaired NRF2 activity, as found in HGPS cells, is sufficient to recapitulate cellular HGPS aging defects.
Reactivation of the NRF2 Pathway Reverses ProgerinInduced Aging Defects
To test whether NRF2 pathway reactivation ameliorates HGPS defects, we introduced constitutively activated NRF2 (caNRF2; see the Supplemental Experimental Procedures) in WT and HGPS cells ( Figure S5A ). In line with CAND1 RNAi results, caNRF2 expression prevented the formation of all tested nuclear defects, as well as lowered GFP-progerin levels (À60%, p < 0.05; Figure S5B ) in WT fibroblasts, and fully restored lamin B1, LAP2, HP1g, and H3K27me3 ( Figures 5A, 5C , and S5F). NRF2 pathway reactivation in HGPS cells decreased progerin protein levels by 59% (p < 0.05; Figure 5B ) and reduced lamin A (À25%, p < 0.05) without altering lamin C levels. In addition, we also tested the effect of four small-molecule NRF2-activating agents on HGPS fibroblasts. Oltipraz (Magesh et al., 2012) ameliorated lamin B1 and HP1g levels by 73% and 53% (100% = difference between WT and HGPS cells), respectively (p < 0.05; Figure S5C) , and showed some effect in reducing LAP2 and H3K27me3 defects (30%-38%, p > 0.05). CPDT restored lamin B1 levels and ameliorated HP1g and H3K27me3 defects (52%-79%, p < 0.05), as did the compound AI-1 (Magesh et al., 2012) . CPDT, however, increased gH2AX levels (+35% absolute change; p < 0.05), which we did not observe for other tested compounds ( Figure S5C ). TAT-14, a cell-penetrating NRF2-stabilizing short peptide (Steel et al., 2012) restored HP1g levels and ameliorated H3K27me3 defects (62%; p < 0.05; Figure S5C ). All beneficial effects of NRF2-activating compounds occurred without affecting progerin levels ( Figure S5C ). caNRF2 expression also improved the expression of progerinrepressed NRF2-regulated antioxidant genes (n = 10; Figure S5E ) and lowered ROS levels in HGPS cells to only 39% of WT levels (p < 0.05; Figure 5D ). To test whether reducing oxidative stress itself is sufficient to reverse established HGPS aging defects, we treated HGPS patient cells with the broad-acting antioxidant N-acetyl cysteine (NAC). NAC treatment partially improved gH2AX (18% of WT/HGPS difference, p < 0.05), restored LAP2 and HP1g levels, and ameliorated lamin B1 and H3K27me3 defects (38%-54% of WT/HGPS difference; p < 0.05; Figure 5E ), without affecting endogenous progerin or lamin A or lamin C levels ( Figure S5D ). The observation that increased NRF2 activity by caNRF2 expression or CAND1 knockdown in WT cells does not alter lamin B1, LAP2, HP1g, H3K27me3, gH2AX, and 53BP1 protein levels ( Figures S5G and S5H ), but as expected lowers ROS levels ( Figure S5I ), further indicates that NRF2 pathway reactivation specifically corrects HGPS patient cellular defects, while not affecting the physiological levels of key proteins in these pathways. Overall, these data demonstrate that restoration of the impaired NRF2 pathway in HGPS patient cells ameliorates aging defects in vitro by lowering oxidative stress.
NRF2 Pathway Activation Restores In Vivo Viability of HGPS Mesenchymal Stem Cells
A prominent in vivo defect in HGPS is the reduced ability of MSCs to respond to oxidative stress, limiting their viability in vivo (Zhang et al., 2011) and contributing to reduced stem cell pools in HGPS (Pacheco et al., 2014; Rosengardten et al., 2011) . To test the effect of NRF2 pathway modulation on HGPS MSCs, we generated iPSCs from HGPS patient fibroblasts (henceforth (legend continued on next page) HGPS-iPSCs; see the Experimental Procedures), and their isogenic control in which the LMNA C1824T mutation was genetically corrected (GC-iPSCs; Figure S6A ) (Liu et al., 2011b) . As expected, since LMNA is inactive in iPSCs (Constantinescu et al., 2006; Liu et al., 2011a Liu et al., , 2011b , expression of NRF2-regulated antioxidants was not downregulated in HGPSiPSCs compared to GC-iPSCs ( Figure 6A ). However, in line with progerin impairment of NRF2 activity, reactivation of the LMNA gene upon differentiation of iPSCs into MSCs reduced NRF2 target gene expression in HGPS-iPSC-MSCs compared to GC-iPSC-MSCs ( Figures 6A, S6B , and S6C). This effect was a direct consequence of progerin expression since induced GFP-progerin expression in GC-iPSC-MSCs similarly reduced NRF2 target gene expression ( Figures S6D and S6E ). Reduced NRF2 activity was sufficient to mimic HGPS defects since NRF2 knockdown in GC-iPSC-MSCs decreased expression of NRF2 antioxidant genes ( Figure 6B ), increased oxidative stress ( Figure 6C ), reduced levels of lamin B1, LAP2, and HP1g proteins (p < 0.05; Figures 6D and S6G ), increased frequencies of senescence associated b-galactosidase (SA-b-gal) positive cells (Figure 6E) , and, ultimately, reduced cell survival ( Figure 6F ) comparable to HGPS-iPSC-MSCs ( Figures S6F-S6H ). Conversely, as expected, expression of caNRF2 in GC-iPSC-MSCs increased expression of NRF2 antioxidant genes and thereby lowered ROS levels ( Figures 6H and S6I) . To test the effect of the progerin-NRF2 pathway in vivo, we used an established animal model assay system (Zhang et al., 2011) in which MSCs are implanted into the tibialis anterior muscle and engraftment and survival is measured (Pan et al., 2016; Zhang et al., 2015) (see the Experimental Procedures). As expected by our in vitro observations, the presence of progerin in HGPS-iPSC-MSCs or knockdown of NRF2 in GC-iPSC-MSCs resulted in increased stem cell attrition in the in vivo niche (p < 0.05; Figure 6L ). In contrast, overexpression of caNRF2 (E82G; see the Experimental Procedures) or Oltipraz-mediated NRF2 activation in HGPS-iPSCMSCs increased expression of NRF2-regulated antioxidants ( Figure 6G ), decreased ROS levels ( Figure 6H ), rescued HGPS nuclear defects ( Figure 6I ), and reduced the number of apoptotic ( Figure 6J ) and SA-b-gal-positive cells ( Figure 6K ). Similarly, knockdown of CAND1 in HGPS-iPSC-MSCs reactivated all tested NRF2 target genes ( Figures S6J and S6K) . Importantly, NRF2 pathway reactivation by expression of caNRF2 restored the in vivo viability of HGPS-MSCs ( Figure 6L ). A similar effect was observed by pre-treatment of cells with the mild NRF2 inducer Oltipraz ( Figure 6L ), indicating that the NRF2-mediated rescue effect is not due to massive hyperactivation of the pathway. These data from an HGPS-relevant animal model support an in vivo role of NRF2 as a driver in HGPS pathology.
DISCUSSION
The lamin A mutant isoform progerin causes extensive architectural, epigenetic, redox, and DNA damage defects in the premature aging syndrome HGPS (Gordon et al., 2014; Scaffidi and Misteli, 2006; Viteri et al., 2010) . It is unclear how progerin triggers these defects and discovery of HGPS driver mechanisms is crucial to a molecular understanding and the identification of therapeutic targets of premature and normal aging. Using a high-throughput, high-content cell-based assay, we identify impairment of the longevity-promoting transcription factor NRF2 by progerin as a driver mechanism in HGPS etiology. NRF2 is a major stress responder that transcriptionally activates antioxidant and cytoprotective genes through binding to ARE motifs (Lewis et al., 2010) . The sum of our results delineates a mechanism by which progerin sequesters NRF2, and in this way reduces its availability for transcriptional activation of antioxidant genes, resulting in elevated oxidative damage and consequentially an array of HGPS defects. Given that progerin is a highly expressed long-lived protein (Boisvert et al., 2012) , whereas NRF2 is low in abundance and short-lived (McMahon et al., 2004) , progerin/NRF2 sequestration is expected to drastically reduce the availability of NRF2 for the formation of functional transcription factor complexes at ARE motifs. In agreement, we find that experimental elevation of NRF2 levels in HGPS cells restored NRF2 pathway activity, further suggesting that the availability of NRF2, and not of other NRF2/ARE complex co-factors, is limited in HGPS.
A likely scenario, based on this study and others, for how increased ROS levels contribute to HGPS etiology suggests that aberrant NRF2/progerin interaction reduces expression of antioxidants, increases ROS levels, and thereby causes loss of heterochromatin and increased levels of DNA damage (Frost et al., 2014; Pegoraro et al., 2012; Richards et al., 2011) . We hypothesize that the elevated oxidative stress in HGPS cells is the result of increased ROS formation, due to defective mitochondrial oxidative phosphorylation (Rivera-Torres et al., 2013) , a pathway that is maintained by the progerin-impaired NRF2 target NQO1 (Kwon et al., 2012) , as well as a diminished ROScounteracting antioxidative capacity due to impaired NRF2 activity. Subsequently, increased ROS levels can cause a severe loss of heterochromatin (Frost et al., 2014) , which precedes and by itself is sufficient to activate DNA damage signaling as observed in progerin-inducible fibroblasts (Pegoraro et al., 2009) . That NRF2 activation fully prevents gH2AX and 53BP1 foci formation upon progerin induction in a WT background, but does not reduce these defects in HGPS cells, suggests that progerin renders DNA damage foci partially irreparable through NRF2 pathway-independent mechanisms, in line with previously observed minimal effects on DNA damage in HGPS cells by farnesyl-transferase inhibitors (Liu et al., 2006) and NAC (Richards et al., 2011) . Similarly, nuclear shape alterations, the formation of which was prevented by NRF2 activation in progerin-inducible WT cells, but could not be reversed once established in HGPS patient cells, may be due to insufficient reduction of progerin levels by caNRF2. See also Figure S4 and Table S1 .
Several lines of evidence support the conclusion that the protective function of NRF2 in HGPS is largely independent of an effect on progerin levels. First, lowering ROS levels in HGPS fibroblasts by NAC antioxidant treatment ameliorates HGPS defects without lowering progerin levels. Second, further impairment of NRF2 activity in HGPS fibroblasts by GC-iPSC-MSC shCTRL
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(legend continued on next page)
NRF2 knockdown worsens all tested defects without altering progerin protein levels. Third, using single-cell-level analysis, we observed that even a 50% above-average increase in progerin levels in HGPS patient cells did not account for the increased defects observed in response to H 2 O 2 pro-oxidant treatment. Fourth, increased oxidative stress levels through NRF2 knockdown or H 2 O 2 treatment in WT cells was sufficient to mimic HGPS defects in the absence of progerin. Fifth, when comparing two cell populations with similar progerin levels, but one with activated NRF2 signaling due to CAND1 knockdown, the reduction of progerin alone was insufficient to prevent the formation of other nuclear defects. A possible mechanism for how NRF2 may decrease progerin comes from previous observations that the NRF2-ARE pathway also transcriptionally activates 20S proteasome subunits to aid in the clearance of ROS damaged proteins (Pickering et al., 2013) . A plausible scenario is that reactivation of NRF2 activity in HGPS cells increases the capacity of the proteasome system, which is slightly attenuated in HGPS cells (Viteri et al., 2010) and thereby aids in clearing ROS-damaged proteins, as well as progerin aggregates.
Our results are in line with observations at the organismal level that have demonstrated a contribution of the NRF2 pathway to multiple aspects of premature aging. Genetic disruption of the Nrf2 gene decreases the lifespan of female mice (Yoh et al., 2001) , and hypomorphic mutants of SKN-1, the Caenorhabditis elegans NRF2 homolog, shorten C. elegans lifespan nearly 2-fold (An and Blackwell, 2003) . Furthermore, Nrf2 knockout mice show decreased adipogenic differentiation and high-density lipoprotein (HDL) levels (Tanaka et al., 2008) , intriguingly similar to the global loss of adipose tissue and altered blood-lipid profiles in HGPS patients (Gordon et al., 2005) , and in addition suffer from aging-associated skeletal muscle wasting, retinopathies, and dermal photo-aging (Hirota et al., 2011; Miller et al., 2012; Zhao et al., 2011) . As expected, reported phenotypes in NRF2-targeted mice are milder than in HGPS mice models (Chan et al., 1996) , most likely due to redundancy and biological differences between complete genetic gene disruption and a hypomorphic effect on NRF2 in HGPS.
Although our primary goal was to identify HGPS driver mechanisms, our observations suggest that restoration of NRF2 activity may offer a novel therapeutic strategy for HGPS. Clinical activation of NRF2 in HGPS patients may increase bone mineral density, which is reduced in HGPS patients (Rankin and Ellard, 2006) and has been observed in Nrf2 knockout mice (Ibanez et al., 2014) . NRF2 activation may also decrease the prevalence of atherosclerotic lesions and stroke (Li et al., 2009) , the main causes of death in HGPS patients (Gordon et al., 2014) . Cardiovascular protective effects may further occur due to NRF2 inhibiting NFkB inflammatory responses (Li et al., 2008) , which are detrimental to HGPS (Osorio et al., 2012) . Given that increased NRF2 activity restored in vivo HGPS-iPSC-MSC viability, we expect NRF2 activation to counteract the premature exhaustion of adult stem cell populations that occurs in HGPS patients (Halaschek-Wiener and Brooks-Wilson, 2007) , due to their diminished capacity to respond to oxidative challenges in their hypoxic niches (Liu et al., 2012 (Liu et al., , 2011a Zhang et al., 2011) . Further beneficial effects may originate from the fact that adult stem cells are highly dependent on NRF2 activity to maintain self-renewal ability and lineage commitment (Murakami et al., 2014; Pan et al., 2016) and show altered differentiation in response to reduction of NRF2-regulated MnSOD antioxidant (Michaeloudes et al., 2011) and elevated ROS levels (Mateos et al., 2013) .
Due to these health-promoting effects of NRF2, identification of NRF2-activating small-molecular compounds is a high-value target in drug discovery (Magesh et al., 2012) . Our observation that the FDA-approved drug Oltipraz, as well as other experimental NRF2-activating compounds, improved multiple aging defects in HGPS cells further indicates the potential of NRF2-activating drugs as a novel treatment type in HGPS. In this light, it is also noteworthy that both sulforaphane and resveratrol, both reported to alleviate HGPS symptoms (Gabriel et al., 2015; Liu et al., 2012) , are dependent on NRF2 for their general health-promoting effects in non-HGPS animal models (Ungvari et al., 2010; Zakkar et al., 2009) . Finally, and maybe most intriguingly, the recent finding that lamin A mutants that cause muscular dystrophy cause cytoplasmic KEAP1 aggregation, increased NRF2 activity, and reductive stress (Dialynas et al., 2015) raises the possibility that the defective NRF2 pathway activity may not just be a driver of HGPS, but a common denominator among laminopathies.
EXPERIMENTAL PROCEDURES
Cell Lines and Treatments hTert immortalized doxycycline GFP-progerin inducible human skin fibroblasts (P1 cells) were generated and induced (96 hr) as described (Kubben et al., 2015) . Human HGPS-iPSCs (C1824T LMNA mutation) and their genecorrected isogenic counterparts (GC-iPSC; no LMNA mutation) were generated as described (Liu et al., 2011b) . iPSC MSC differentiation was performed using established protocols (Duan et al., 2015; Zhang et al., 2015; Pan et al., 2016) . Primary HGPS patient skin fibroblasts (Coriell Cell Repository (CCR), AG01972 and AG06297), and age-matched control cell lines (American Type Culture Collection, CRL-1474; CCR, GM00038) were used under conditions as previously described (Pegoraro et al., 2009) . Cell treatments included AI-1 (125 mM), CPDT (60 mM), H 2 O 2 (100, 125 and 250 mM), NAC (10 mM), oltipraz (20, 100 mM), and sulforaphane (5 mM), TAT-14 (100 mM). All compounds were purchased from Sigma, except TAT-14 (Millipore). H 2 O 2 , NAC and TAT-14 were dissolved in PBS, all others in DMSO. Media with compounds were replaced every 48 hr, except for H 2 O 2 which was left unreplaced for 96 hr (Figure 4) , or was replaced with vehicle containing medium after 1 hr of stimulation ( Figure S4G ).
(J and K) Relative amounts of apoptotic cells (J) and SA-b-galactosidase-positive cells in GC-and HGPS-iPSC-MSC-expressing caNRF2 or treated with Oltipraz (K) (20 mM; 3 weeks). n > 300. *p < 0.05. (L) In vivo MSC implantation assay for the indicated conditions (Oltipraz: 20 mM; 3 weeks) (n = 3-5). *p < 0.05 for indicated comparisons: HGPS versus GC; GC/ shNRF2 versus GC/shCTRL; HGPS/caNRF2 versus HGPS/CTRL; HGPS/Oltipraz versus HGPS/vehicle. For all bar graphs, values represent averages ± SD from at least three experiments. See also Figure S6 and Table S1 .
siRNA Transfection in a 384-Well Format Reverse siRNA transfections were carried out in quadruplicate in a 384-well format (Perkin Elmer Cell carrier plates) in the presence of doxycycline (1 mg/ ml) as described (Pegoraro et al., 2009 ) with pooled siRNA oligos (50nM; 4 siRNAs/target) from the Dharmacon siGENOMESMARTpool siRNA Human Ubiquitin Conjugation subset 1 and 2 libraries. Positive and negative controls consisted of GFP-targeting and non-targeting siRNA (50nM; Ambion, #AM4626, #AM4611G), respectively. Transfected cells were incubated overnight, after which 60 ml of antibiotic and doxycycline (1 mg/ml) containing medium was added and cells were incubated for another 3 days (37 C, 5% CO 2 ).
High-Throughput High-Content Imaging Analysis IF staining was performed (see the Supplemental Experimental Procedures), after which cells were imaged in a single optimal focal plane (24 fields/ well, 20x water immersion objective) on an Opera high-throughput spinning-disk confocal microscopy system (Perkin Elmer), using sequential acquisitions with a 405/640, 488 and a 568 nm excitation laser. Immunofluorescence (IF) stainings were analyzed at the singular cell level with a customized algorithm (Kubben et al., 2015) using DAPI-based nuclear segmentation to quantify the total nuclear intensity for all indicated targets, and a contrast-based algorithm to detect 53BP1 foci numbers and total integrated intensity for gH2AX foci (Kubben et al., 2015) . 500-2000 cells were analyzed per condition, and quantifitions were depicted as an average of the total cell population. iPSC IF experiments were captured with a Leica SP5 confocal microscope, and total nuclear intensity was quantified with ImageJ software. Normalized Z-score RNAi screen values were calculated using CellHTS2 (Pegoraro et al., 2012) . Z'-scores for the assays' parameters were 0.15 (lamin B1), 0.38 (gH2AX) and 0.74 (progerin). siRNA pools with cell numbers above 50% of the negative control, and with a Z-score < À1.65 for lamin B1 or > 1.65 for gH2AX, together with a Z-score > 2.0 for progerin, were selected initial candidates, out of which the strongest candidates (Z-score < À2.0 for combined laminB1 and gH2AX effects; see Table S2 ) were pursued for secondary validation using On-Target Plus pooled siRNAs (Dharmacon, 4/target).
Statistical Analysis
All RNAi screening follow-up experiments are depicted as averages of three biological replicates, each consisting of at least three technical replicates, unless stated otherwise, and analyzed by Student's t test in Graphpad Prism. 
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